232 related articles for article (PubMed ID: 34813633)
21. Morphological characteristics of the subfoveal choroid and their association with visual acuity in postoperative patients with unilateral congenital cataracts.
Zhou Y; Wang J; Jin L; Chen W; Wang Q; Chen H; Chen J; Li Z; Lin Z; Li X; Li J; Lin H; Lin D; Chen W
Ann Transl Med; 2022 Jul; 10(13):726. PubMed ID: 35957713
[TBL] [Abstract][Full Text] [Related]
22. Assessment of choroidal vascularity and choriocapillaris blood perfusion in Chinese preschool-age anisometropic hyperopic amblyopia children.
Hui W; Xiaofeng H; Hua X; Yihan D; Yong T
Front Pediatr; 2022; 10():1056888. PubMed ID: 36467467
[TBL] [Abstract][Full Text] [Related]
23. Changes in Choroidal Thickness After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy.
Padrón-Pérez N; Arias L; Rubio M; Lorenzo D; García-Bru P; Català-Mora J; Caminal JM
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):1119-1124. PubMed ID: 29490349
[TBL] [Abstract][Full Text] [Related]
24. Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study.
Agrawal R; Gupta P; Tan KA; Cheung CM; Wong TY; Cheng CY
Sci Rep; 2016 Feb; 6():21090. PubMed ID: 26868048
[TBL] [Abstract][Full Text] [Related]
25. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
Smith JR; Rosenbaum JT; Wilson DJ; Doolittle ND; Siegal T; Neuwelt EA; Pe'er J
Ophthalmology; 2002 Sep; 109(9):1709-16. PubMed ID: 12208721
[TBL] [Abstract][Full Text] [Related]
26. Changes in choroidal structure following intravitreal aflibercept therapy for retinal vein occlusion.
Mitamura Y; Enkhmaa T; Sano H; Niki M; Murao F; Egawa M; Sonoda S; Sakamoto T
Br J Ophthalmol; 2021 May; 105(5):704-710. PubMed ID: 32620686
[TBL] [Abstract][Full Text] [Related]
27. Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration.
Pellegrini M; Bernabei F; Mercanti A; Sebastiani S; Peiretti E; Iovino C; Casini G; Loiudice P; Scorcia V; Giannaccare G
Graefes Arch Clin Exp Ophthalmol; 2021 Apr; 259(4):911-918. PubMed ID: 33048236
[TBL] [Abstract][Full Text] [Related]
28. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
Ünlü C; Erdogan G; Gunay BO; Kardes E; Akcay BI; Ergin A
Int Ophthalmol; 2017 Feb; 37(1):147-158. PubMed ID: 27154721
[TBL] [Abstract][Full Text] [Related]
29. Choroidal vascularity index in thyroid-associated ophthalmopathy.
Yeter V; Koçak N; Subaşı M; Parlak U
Can J Ophthalmol; 2023 Feb; 58(1):27-33. PubMed ID: 34324874
[TBL] [Abstract][Full Text] [Related]
30. INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA: Case Series.
Guneri Beser B; Demirci H
Retina; 2024 Feb; 44(2):353-359. PubMed ID: 37883576
[TBL] [Abstract][Full Text] [Related]
31. Intraocular chemotherapy for vitreoretinal lymphoma: A review.
Kvopka M; Lake SR; Smith JR
Clin Exp Ophthalmol; 2020 Mar; 48(2):240-248. PubMed ID: 31680408
[TBL] [Abstract][Full Text] [Related]
32. Choroidal vascular changes in age-related macular degeneration.
Koh LHL; Agrawal R; Khandelwal N; Sai Charan L; Chhablani J
Acta Ophthalmol; 2017 Nov; 95(7):e597-e601. PubMed ID: 28391615
[TBL] [Abstract][Full Text] [Related]
33. Repeated IL-10 measurement in aqueous humor and OCT imaging are valuable tools to monitor intraocular lymphoma treated with intravitreal injections of methotrexate.
Saleh M; Nikolitch K; Bourcier T; Speeg C; Gaucher D
Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):761-4. PubMed ID: 21755434
[No Abstract] [Full Text] [Related]
34. Subfoveal choroidal thickness change after intravitreal ranibizumab for idiopathic choroidal neovascularization.
Cao XS; Peng XY; You QS; Zhang YP; Jonas JB
Retina; 2014 Aug; 34(8):1554-9. PubMed ID: 24667570
[TBL] [Abstract][Full Text] [Related]
35. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.
Larkin KL; Saboo US; Comer GM; Forooghian F; Mackensen F; Merrill P; Sen HN; Singh A; Essex RW; Lake S; Lim LL; Vasconcelos-Santos DV; Foster CS; Wilson DJ; Smith JR
Br J Ophthalmol; 2014 Jan; 98(1):99-103. PubMed ID: 24158837
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India.
Rishi P; Manchegowda PT; Gondhale HP; Rishi E; Das K; Krishnakumar S; Raja T; Biswas J
Int Ophthalmol; 2021 Jul; 41(7):2495-2504. PubMed ID: 33730314
[TBL] [Abstract][Full Text] [Related]
37. Choroidal vascularity index changes during the Valsalva manoeuvre in healthy volunteers.
Sevik MO; Çam F; Aykut A; Dericioğlu V; Şahin Ö
Ophthalmic Physiol Opt; 2022 Mar; 42(2):367-375. PubMed ID: 34913506
[TBL] [Abstract][Full Text] [Related]
38. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.
Hashida N; Nakai K; Saitoh N; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):687-93. PubMed ID: 24549401
[TBL] [Abstract][Full Text] [Related]
39. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
40. Enhanced depth imaging optical coherence tomography of the choroid in central retinal vein occlusion.
Tsuiki E; Suzuma K; Ueki R; Maekawa Y; Kitaoka T
Am J Ophthalmol; 2013 Sep; 156(3):543-547.e1. PubMed ID: 23688711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
